This content is published by the UTCTS Health Review Desk for informational and educational purposes only. It does not constitute medical advice. Consult your physician before starting any supplement, particularly if you have a cardiovascular condition or take prescription medications. UTCardiothoracicSurgery.com Editorial Team | July 2026. This article may contain affiliate links. Purchases made through links in this article may generate a commission at no additional cost to you, without affecting editorial objectivity. FTC disclosure required by 16 C.F.R. Part 255.
Quick Answer: Triple Green Farms CBD Gummies are a hemp-derived cannabidiol supplement marketed for relaxation and general wellness. CBD is a potent inhibitor of cytochrome P450 enzymes — the same liver enzymes that metabolize warfarin, many statins, calcium channel blockers, and numerous cardiac medications. This interaction profile makes CBD one of the most pharmacologically significant supplements for cardiac patients to discuss with their physicians.
Why CBD Demands Cardiac-Specific Evaluation
Cannabidiol products have become ubiquitous in the wellness market, yet most reviews focus on relaxation, sleep, and general well-being without addressing CBD's well-documented drug metabolism interactions. For the millions of Americans taking cardiac medications, this is a critical oversight. CBD inhibits CYP3A4 and CYP2C19 — two cytochrome P450 enzyme pathways responsible for metabolizing a substantial percentage of cardiovascular drugs. This does not mean CBD is inherently dangerous, but it does mean that CBD use in cardiac patients is a pharmacological event requiring physician awareness. The UTCTS Health Review Desk treats CBD reviews as medication interaction evaluations, not lifestyle product assessments.
Product Overview: Triple Green Farms CBD Gummies
Triple Green Farms CBD Gummies are a hemp-derived cannabidiol supplement in gummy format, with individual gummies typically containing 5 to 25 mg of CBD per piece. The company markets organic hemp sourcing and third-party testing for potency and purity verification. The gummy base typically includes pectin or gelatin, natural flavors, and sweeteners. Some formulations incorporate complementary cannabinoids (CBN, CBG) or adaptogenic herbs such as ashwagandha. The product is positioned for relaxation support, sleep quality, stress management, and general wellness. CBD works through the endocannabinoid system, a cell-signaling network involved in mood regulation, inflammatory response, pain perception, and sleep architecture. The product does not contain psychoactive levels of THC and is not intended to produce intoxication.
The Label vs. Marketing Analysis
Triple Green Farms emphasizes third-party testing and transparent sourcing, which represent positive quality signals in a CBD market where consistency is a documented industry-wide challenge. Marketing materials describe broad wellness benefits including calm, sleep support, stress reduction, muscle recovery, and mood balance. The UTCTS Health Review Desk notes that while individual users may experience some of these effects, the CBD research base is strongest for specific applications — notably anxiety (modest evidence from small trials), certain epilepsy syndromes (FDA-approved Epidiolex), and possibly pain modulation — rather than the broad-spectrum wellness positioning typical of gummy products. The marketing appropriately avoids disease treatment claims. However, no specific COA (Certificate of Analysis) data was identified on publicly available marketing materials at the time of this review. Readers should request batch-specific third-party test results before purchasing any CBD product, as potency discrepancies between label claims and actual content are well-documented across the CBD industry.
Ingredient Evidence and Dose Context
Cannabidiol (CBD): CBD has been studied in clinical settings for anxiety, epilepsy, chronic pain, and inflammatory conditions. FDA has approved one CBD medication (Epidiolex) for specific seizure disorders at doses of 5-20 mg/kg/day — far higher than typical gummy supplementation. Most wellness-dose CBD products deliver 10-50 mg daily, which falls below clinical trial doses for most studied conditions. Evidence for relaxation and sleep support at these lower doses exists primarily in survey-based research and small pilot studies, not large randomized controlled trials.
Complementary cannabinoids (CBN, CBG — if included): Preliminary research suggests CBN may have mild sedative properties and CBG may have anti-inflammatory potential. Human clinical trial data for both remains extremely limited.
Adaptogenic herbs (ashwagandha, if included): Ashwagandha has more robust clinical evidence for stress and anxiety reduction than CBD at supplement doses, with multiple RCTs supporting modest efficacy. However, ashwagandha has its own interaction profile relevant to thyroid medications and immunosuppressants.
Cardiac Safety Profile
CBD's cardiovascular drug interaction profile is among the most clinically significant in the supplement category. The UTCTS Health Review Desk identifies the following specific interactions:
- Blood thinners — warfarin (Coumadin): CBD inhibits CYP2C9 and CYP3A4, both of which metabolize warfarin. Published case reports document significant INR elevation in patients adding CBD to stable warfarin regimens. This interaction is well-documented and potentially dangerous, increasing bleeding risk. Patients on warfarin should consider CBD use only with direct physician oversight and increased INR monitoring frequency.
- Direct oral anticoagulants (apixaban, rivaroxaban): These newer blood thinners are metabolized through CYP3A4. CBD's inhibition of this enzyme may increase plasma levels of these drugs, potentially increasing bleeding risk. Unlike warfarin, DOACs lack simple monitoring tests like INR, making this interaction harder to detect clinically.
- Statins (atorvastatin, simvastatin, lovastatin): Several statins are CYP3A4 substrates. CBD inhibition of this pathway could increase statin blood levels, potentially increasing the risk of myopathy and rhabdomyolysis. Rosuvastatin and pravastatin, which use different metabolic pathways, may carry lower interaction risk.
- Calcium channel blockers (amlodipine, diltiazem, verapamil): These are CYP3A4 substrates. CBD could potentiate their hypotensive effects by increasing drug plasma concentrations. Symptoms may include excessive blood pressure reduction, dizziness, and edema.
- Beta-blockers (metoprolol, propranolol): Metoprolol is metabolized by CYP2D6, which CBD also inhibits. Increased beta-blocker levels could cause excessive heart rate reduction and hypotension.
- Antiplatelet agents (clopidogrel): Clopidogrel is a prodrug that requires CYP2C19 activation. CBD inhibition of CYP2C19 could theoretically reduce clopidogrel's antiplatelet effectiveness, which is a serious concern for patients with coronary stents who depend on clopidogrel for stent thrombosis prevention.
- Antiarrhythmic medications (amiodarone): Amiodarone is a CYP3A4 substrate with a narrow therapeutic index. CBD-mediated enzyme inhibition could increase amiodarone to toxic levels, potentially causing thyroid dysfunction, pulmonary toxicity, or proarrhythmic effects.
The breadth of CBD's enzyme inhibition makes it one of the highest-interaction-risk supplements available over the counter. Cardiac patients taking any of the above medication categories should not initiate CBD use without explicit physician discussion.
User-Reported Outcomes
User reviews for Triple Green Farms emphasize relaxation, improved sleep, and reduced daily stress. Athletes report post-workout recovery benefits. The gummy format receives consistent praise for taste and convenience. However, individual responses to CBD vary considerably based on endocannabinoid system sensitivity, baseline stress levels, concurrent medications, and dosing. Results may take 1 to 2 weeks to become noticeable. Independent user review data from verified third-party platforms for this specific brand is limited, making it difficult to assess satisfaction rates beyond manufacturer-curated testimonials.
Pricing and Refund Terms
Triple Green Farms CBD Gummies are available through the official company website, online retailers, and select health stores. Single bottles typically range from $35 to $65 depending on gummy count and CBD concentration. Multi-bottle packages and subscription services offer 15-25% discounts. Promotional pricing and seasonal sales are common. Specific refund policy terms should be verified before purchase. Pricing is subject to change. Verify current pricing on the manufacturer's official listing.
Buyer Takeaway
Triple Green Farms offers a standard CBD gummy product with positive quality signals (third-party testing, organic sourcing claims). For general wellness consumers not taking prescription medications, CBD gummies at standard supplement doses carry a favorable safety profile with mild reported side effects. However, for cardiac patients — the readership this review specifically serves — CBD's cytochrome P450 enzyme inhibition creates a uniquely broad drug interaction profile that touches warfarin, DOACs, statins, calcium channel blockers, beta-blockers, antiplatelet agents, and antiarrhythmics. This is not a product to add casually to a cardiac medication regimen. The UTCTS Health Review Desk recommends that any cardiac patient considering CBD supplementation bring their full medication list to a pharmacist or cardiologist for a formal interaction screening before their first dose.
Related Reading
- UTCardiothoracicSurgery.com Home — Browse cardiac-safety supplement reviews
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for educational purposes only and does not constitute medical advice. Results vary by individual. Consult your physician before starting any supplement, particularly if you take cardiovascular or metabolic medications.